Clinical Trials Directory

Trials / Completed

CompletedNCT00311363

Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.

A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
327 (actual)
Sponsor
XenoPort, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).

Detailed description

This study was a multicenter, blinded, randomized withdrawal study in subjects with primary Restless Legs Syndrome (RLS). Eligible subjects were initially enrolled in a 24-week single blind (SB) treatment period during which they received XP13512. Subjects who completed the initial treatment period and met the responder criteria were then randomized 1:1 to receive either XP13512 or placebo during the 12-week double-blind (DB) treatment period. The primary study objective was to assess the maintenance of efficacy of XP13512 1200 mg taken once daily in the long-term treatment of subjects with primary RLS. The secondary study objectives were to assess maintenance of improvements in sleep outcomes and quality of life, and to assess the safety and tolerability of XP13512 in the treatment of primary RLS subjects.

Conditions

Interventions

TypeNameDescription
DRUGGEn (XP13512)1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
DRUGGEn (XP13512)1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
DRUGPlaceboPlacebo, orally, once daily for 12 weeks following single blind 24-week phase

Timeline

Start date
2006-04-01
Primary completion
2007-11-01
Completion
2007-11-01
First posted
2006-04-05
Last updated
2013-07-22
Results posted
2011-05-25

Source: ClinicalTrials.gov record NCT00311363. Inclusion in this directory is not an endorsement.